Summary
We have studied the pharmacokinetics of bendazac and its major metabolite, 5-hydroxybendazac, in 11 patients with hepatic cirrhosis after the oral administration of a single 500 mg tablet of bendazac-lysine, and compared them with those obtained from 10 healthy adults.
The rate of absorption of bendazac, as assessed by tmax and Cmax, is similar in patients and in healthy subjects.
The drug is eliminated mostly by metabolism in healthy adults, more than 60% of the dose being excreted in the urine as 5-hydroxybendazac and its glucuronide. Hepatic insufficiency impairs this metabolism, a two-fold decrease in apparent plasma clearance (CL/f) being observed in the patients.
Although the plasma unbound fraction of bendazac is increased in patients (the drug is highly bound to plasma albumin), the apparent volume of distribution (V/f) is unchanged. In consequence, the half-life of bendazac is increased two-fold in the patients.
Impairment of metabolism decreases the formation of 5-hydroxybendazac, but metabolism remains the main route of its elimination. Renal excretion of bendazac accounts for about 10% of the dose in both patients with cirrhosis and healthy subjects.
We conclude that in patients with severe hepatic insufficiency the daily dose of bendazac-lysine should be havled.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barillari G (1983) Oral absorption of bendazac-lysine salt in man after repeated administrations Pharmacol Res Commun 15: 461–471
Blaschke TF (1977) Protein binding and kinetics of drugs in liver disease. Clin Pharmacokinet 2: 32–44
Bonomi L, Marchini G, De Franco I, Perfetti S, De Gregorio M (1983) Bendazac lysine salt in treatment of cataract — a controlled study. Curr Ther Res Clin Exp 33: 727–732
Caramazza R, De Gregorio M, Pioggia M (1985) Valutazione clinica controllata del bendazac lisina nella cataratta senile in uno studio policentrico. Analisi dell'effetto di sei mesi di trattamento. Boll Ocul 64: 1–18
Catanese B, Barillari G, Iorio E, Silvestrini B (1982) A comparative study of the oral absorption in man of bendazac and its lysine salt. Boll Chim Farm 121: 87–90
Fehske KJ, Müller WE, Wollert U (1981) The location of drug binding sites in human serum albumin. Biochem Pharmacol 30: 687–692
Øie S, Tozer TN (1979) Effect of altered plasma protein binding on apparent volume of distribution J Pharm Sci 68: 1203–1205
Gomeni C, Gomeni R (1978) Igpharm: Interactive graphic package for pharmacokinetic analysis. Comput Biomed Res 11: 345–361
Recupero SM, Librando A, Mannino G (1984) Valutazione clinica sull'impiego della bendalina nella terapia della cataratta. Clin Ocul Pat Oculare 5: 301–306
Rovei V, Campiston G, Dueymes JM, Ego D, Conte JJ, Houin G (1987a) Pharmacokinetics of bendazac-lysine and 5-hydroxy-bendazac in patients with renal insufficiency. Eur J Clin Pharmacol 33: 303–310
Rovei V, Ego D, Catanese B (1987b) Pharmacokinetics and metabolism of bendazac-lysine. In: D'Ermo F (ed) Recent developments in pharmacological treatment of cataract. Kugler Publications/Ghedini Editore, Amsterdam, pp 15–23
Silvestrini B, Catanese B, Barillari G, Iorio E, Valeri P (1983) Basic data supporting the use of the L-lysine salt of bendazac in cataract. Int J Tissue React 5: 217–225
Sudlow G (1978) The specificity of binding sites on serum albumin. In: Tillement JP. Advances in pharmacology and therapeutics, vol. 7. Biochemical clinical pharmacology. Pergamon Press Publisher, pp 113–123
Tozer TN (1981) Concepts basic to pharmacokinetics. Pharmacol Ther 12: 109–131
Vallner JJ (1977) Binding of drugs by albumin and plasma protein. J Pharm Sci 66: 447–465
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rovei, V., Escourrou, J., Campistron, G. et al. The pharmacokinetics of bendazac-lysine and 5-hydroxybendazac, its main metabolite, in patients with hepatic cirrhosis. Eur J Clin Pharmacol 35, 391–396 (1988). https://doi.org/10.1007/BF00561370
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561370